Phesgo comes in a single-dose vial and can be dosed as a subcutaneous injection, while at the moment breast cancer patients the two anti-HER2 drugs separately receive Herceptin as a subcutaneous ...

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...

The integration will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician.

CuraTeQ Biologics s.r.o., announced that the CHMP of the European Medicines Agency has adopted a positive opinion ...

For instance, the drug Herceptin has been effective for forms of breast cancers with tumors expressing a particular protein (HER2 positive). Another class of drugs (CDK4/6 inhibitors), which work with ...

Phesgo is already approved as a SC alternative to intravenous (IV) Perjeta and Herceptin for people with HER2-positive early-stage and metastatic breast cancer in more than 120 countries/regions. In ...

The positive opinion is based on demonstrating comprehensive analytical similarity and clinically no meaningful differences between Dazublys and the reference biologic product Herceptin in terms ...

1-4 Phesgo is already approved as a SC alternative to intravenous (IV) Perjeta and Herceptin for people with HER2-positive early-stage and metastatic breast cancer in more than 120 countries/regions.

The integration will streamline access to Lilly's FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician. As part ...

It's back!’” And that’s exactly what happened. Her doctor scheduled more chemo, radiation, and infusions of a drug called Herceptin to combat her HER2-positive cancer. She’d already lost ...